Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults

Vaccine efficacy is based on clinical data. Currently, the assessment of immune response after SARS-CoV-2 vaccination is scarce. A total of 52 healthcare workers were immunized with the same lot of BNT162b2 vaccine. The immunological response against the vaccine was tested using a T-specific assay b...

Full description

Bibliographic Details
Main Authors: David San Segundo, Alejandra Comins-Boo, Juan Irure-Ventura, Mónica Renuncio-García, Adriel Roa-Bautista, Elena González-López, David Merino-Fernández, Patricia Lamadrid-Perojo, Marta Alonso-Peña, Javier Gonzalo Ocejo-Vinyals, Maria Gutiérrez-Larrañaga, Sandra Guiral-Foz, Marcos López-Hoyos
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/9/8/868
id doaj-a74cfb5dbe7e4a70a91d544175a3cf4b
record_format Article
spelling doaj-a74cfb5dbe7e4a70a91d544175a3cf4b2021-08-26T13:32:33ZengMDPI AGBiomedicines2227-90592021-07-01986886810.3390/biomedicines9080868Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in AdultsDavid San Segundo0Alejandra Comins-Boo1Juan Irure-Ventura2Mónica Renuncio-García3Adriel Roa-Bautista4Elena González-López5David Merino-Fernández6Patricia Lamadrid-Perojo7Marta Alonso-Peña8Javier Gonzalo Ocejo-Vinyals9Maria Gutiérrez-Larrañaga10Sandra Guiral-Foz11Marcos López-Hoyos12Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainAutoimmunity and Transplantation Research Group, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainAutoimmunity and Transplantation Research Group, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainAutoimmunity and Transplantation Research Group, Research Institute “Marqués de Valdecilla” (IDIVAL), 39011 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainImmunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, SpainVaccine efficacy is based on clinical data. Currently, the assessment of immune response after SARS-CoV-2 vaccination is scarce. A total of 52 healthcare workers were immunized with the same lot of BNT162b2 vaccine. The immunological response against the vaccine was tested using a T-specific assay based on the expression of CD25 and CD134 after stimulation with anti-N, -S, and -M specific peptides of SARS-CoV-2. Moreover, IgG anti-S2 and -RBD antibodies were detected using ELISA. Furthermore, the cell subsets involved in the response to the vaccine were measured in peripheral blood by flow cytometry. Humoral-specific responses against the vaccine were detected in 94% and 100% after the first and second doses, respectively. Therefore, anti-S T-specific responses were observed in 57% and 90% of the subjects after the first and second doses of the vaccine, respectively. Thirty days after the second dose, significant increases in T helper 1 memory cells (<i>p</i> < 0.001), peripheral memory T follicular helper (pT<sub>FH</sub>) cells (<i>p</i> < 0.032), and switched memory (<i>p</i> = 0.005) were observed. This study describes the specific humoral and cellular immune responses after vaccination with the new mRNA-based BNT162b2 vaccine. A mobilization of T<sub>FH</sub> into the circulation occurs, reflecting a specific activation of the immune system.https://www.mdpi.com/2227-9059/9/8/868SARS-CoV-2vaccinesT-specific responseB-specific responseT follicular helper cells
collection DOAJ
language English
format Article
sources DOAJ
author David San Segundo
Alejandra Comins-Boo
Juan Irure-Ventura
Mónica Renuncio-García
Adriel Roa-Bautista
Elena González-López
David Merino-Fernández
Patricia Lamadrid-Perojo
Marta Alonso-Peña
Javier Gonzalo Ocejo-Vinyals
Maria Gutiérrez-Larrañaga
Sandra Guiral-Foz
Marcos López-Hoyos
spellingShingle David San Segundo
Alejandra Comins-Boo
Juan Irure-Ventura
Mónica Renuncio-García
Adriel Roa-Bautista
Elena González-López
David Merino-Fernández
Patricia Lamadrid-Perojo
Marta Alonso-Peña
Javier Gonzalo Ocejo-Vinyals
Maria Gutiérrez-Larrañaga
Sandra Guiral-Foz
Marcos López-Hoyos
Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
Biomedicines
SARS-CoV-2
vaccines
T-specific response
B-specific response
T follicular helper cells
author_facet David San Segundo
Alejandra Comins-Boo
Juan Irure-Ventura
Mónica Renuncio-García
Adriel Roa-Bautista
Elena González-López
David Merino-Fernández
Patricia Lamadrid-Perojo
Marta Alonso-Peña
Javier Gonzalo Ocejo-Vinyals
Maria Gutiérrez-Larrañaga
Sandra Guiral-Foz
Marcos López-Hoyos
author_sort David San Segundo
title Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
title_short Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
title_full Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
title_fullStr Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
title_full_unstemmed Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
title_sort immune assessment of bnt162b2 m-rna-spike based vaccine response in adults
publisher MDPI AG
series Biomedicines
issn 2227-9059
publishDate 2021-07-01
description Vaccine efficacy is based on clinical data. Currently, the assessment of immune response after SARS-CoV-2 vaccination is scarce. A total of 52 healthcare workers were immunized with the same lot of BNT162b2 vaccine. The immunological response against the vaccine was tested using a T-specific assay based on the expression of CD25 and CD134 after stimulation with anti-N, -S, and -M specific peptides of SARS-CoV-2. Moreover, IgG anti-S2 and -RBD antibodies were detected using ELISA. Furthermore, the cell subsets involved in the response to the vaccine were measured in peripheral blood by flow cytometry. Humoral-specific responses against the vaccine were detected in 94% and 100% after the first and second doses, respectively. Therefore, anti-S T-specific responses were observed in 57% and 90% of the subjects after the first and second doses of the vaccine, respectively. Thirty days after the second dose, significant increases in T helper 1 memory cells (<i>p</i> < 0.001), peripheral memory T follicular helper (pT<sub>FH</sub>) cells (<i>p</i> < 0.032), and switched memory (<i>p</i> = 0.005) were observed. This study describes the specific humoral and cellular immune responses after vaccination with the new mRNA-based BNT162b2 vaccine. A mobilization of T<sub>FH</sub> into the circulation occurs, reflecting a specific activation of the immune system.
topic SARS-CoV-2
vaccines
T-specific response
B-specific response
T follicular helper cells
url https://www.mdpi.com/2227-9059/9/8/868
work_keys_str_mv AT davidsansegundo immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT alejandracominsboo immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT juanirureventura immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT monicarenunciogarcia immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT adrielroabautista immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT elenagonzalezlopez immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT davidmerinofernandez immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT patricialamadridperojo immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT martaalonsopena immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT javiergonzaloocejovinyals immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT mariagutierrezlarranaga immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT sandraguiralfoz immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
AT marcoslopezhoyos immuneassessmentofbnt162b2mrnaspikebasedvaccineresponseinadults
_version_ 1721194846634377216